Reuters logo
BRIEF-Tapimmune says on track to achieve 50 pct enrollment in ongoing phase 2 dosing study of TPIV 200
May 31, 2017 / 9:44 PM / 4 months ago

BRIEF-Tapimmune says on track to achieve 50 pct enrollment in ongoing phase 2 dosing study of TPIV 200

May 31 (Reuters) - Tapimmune Inc

* Tapimmune provides first quarter 2017 corporate and clinical update

* Says for 2Q 2017: on track to achieve 50% enrollment in ongoing phase 2 dosing study of TPIV 200 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below